Familial Mediterranean Fever Market

Market Overview:

The 7 major familial Mediterranean fever markets are expected to exhibit a CAGR of 4.31% during 2024-2034.

The familial Mediterranean fever market has been comprehensively analyzed in IMARC's new report titled "Familial Mediterranean Fever Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Familial Mediterranean fever (FMF) refers to a rare hereditary autoinflammatory disorder characterized by recurrent and abrupt episodes of fever, along with painful inflammation of various serous membranes, most notably the peritoneum, pleura, and joints. It primarily affects individuals of Mediterranean descent, particularly those from regions like Turkey, Armenia, and the Middle East. During FMF episodes, patients experience symptoms, such as a high fever, severe abdominal pain, chest pain due to pleuritis, and swollen joints. These episodes typically last for 1–3 days and can recur irregularly. The inflammation is triggered by mutations in the MEFV gene that encodes the protein pyrin. This variation leads to the dysregulation of inflammatory processes and results in the characteristic symptoms of the disease. The diagnosis of FMF involves clinical evaluation, assessing the patient's medical history, and recognizing the recurrent pattern of indications. The healthcare provider will also recommend genetic testing to confirm the diagnosis.

The increasing cases of genetic aberrations within the MEFV gene, resulting in recurrent episodes of fever and inflammation in various body parts, are primarily driving the familial Mediterranean fever market. In addition to this, the inflating utilization of effective medications, including colchicine, which helps to manage the condition's symptoms and reduce the frequency of debilitating episodes, is also creating a positive outlook for the market. Moreover, the widespread adoption of supportive therapies, such as non-steroidal anti-inflammatory drugs (NSAIDs), to alleviate pain, inflammation, and other associated discomforts, is further bolstering the market growth. Apart from this, the rising usage of genetic counseling owing to its several benefits, like assisting patients and families in comprehending the hereditary nature of FMF, making informed decisions, and undertaking necessary precautions, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of targeted therapies tailored to address specific genetic abnormalities linked to FMF is also augmenting the market growth. These agents are designed to modulate the aberrant immune responses underlying the disease, thereby improving the quality of life for people suffering from the condition. Furthermore, the escalating demand for gene editing techniques, including CRISPR-Cas9 technologies, since they work by precisely modifying the flawed genetic sequences associated with the disorder, is expected to drive the familial Mediterranean fever market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the familial Mediterranean fever market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for familial Mediterranean fever and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the familial Mediterranean fever market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the familial Mediterranean fever market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the familial Mediterranean fever market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current familial Mediterranean fever marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the familial Mediterranean fever market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the familial Mediterranean fever market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the familial Mediterranean fever market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of familial Mediterranean fever across the seven major markets?
• What is the number of prevalent cases (2018-2034) of familial Mediterranean fever by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of familial Mediterranean fever by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with familial Mediterranean fever across the seven major markets?
• What is the size of the familial Mediterranean fever patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of familial Mediterranean fever?
• What will be the growth rate of patients across the seven major markets?
   

Familial Mediterranean Fever: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for familial Mediterranean fever drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the familial Mediterranean fever market?
• What are the key regulatory events related to the familial Mediterranean fever market?
• What is the structure of clinical trial landscape by status related to the familial Mediterranean fever market?
• What is the structure of clinical trial landscape by phase related to the familial Mediterranean fever market?
• What is the structure of clinical trial landscape by route of administration related to the familial Mediterranean fever market?